0001293310 false 0001293310 2022-04-12 2022-04-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 12, 2022

 

Humanigen, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35798   77-0557236
(State or other Jurisdiction of
Incorporation)		   (Commission File No.)  

(IRS Employer Identification No.)

 

 

830 Morris Turnpike, 4th Floor 

Short Hills, New Jersey 07078 

 

(Address of principal executive offices, including zip code)

 

(973) 200-3010

(Registrant’s telephone number, including area code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock HGEN The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

     
 

 

Item 7.01. Regulation FD Disclosure

 

A copy of the presentation Humanigen, Inc. (the “Company”) will use during its meetings with investors commencing April 12, 2022 is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In addition, this presentation will be made available on the Company's website, www.humanigen.com.

 

Certain Information

 

The information in this Item 7.01, including Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, except to the extent expressly set forth by specific reference in such a filing.

 

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

 

Exhibit No. Exhibit Description
   
99.1 Humanigen, Inc. Executive Overview April 2022
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

     
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

           

  Humanigen, Inc.
   
  By:  /s/ Cameron Durrant  
    Name: Cameron Durrant
Title:   Chairman of the Board and Chief Executive Officer

 

Dated: April 12, 2022

  

 

 

 

 

 

Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Humanigen Charts.
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Humanigen Charts.